読み込み中
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
前日終値
$14.34
+$0.35 · +2.50%
日中の時刻はETです。市場データは遅延する場合があります。
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
日中レンジ
現在 $14.34
52週レンジ
現在 $14.34
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
57
適正価値
センチメント
56
まちまち
リスク
45
やや高いリスク
モメンタム
52
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
日中レンジ
現在 $14.34
52週レンジ
現在 $14.34
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$26.00
上昇余地（81.31%）この株式へのエクスポージャーを報告している上場投資信託です。
ARK Genomic Revolution ETFARKG2199.06万1.07%15.57億 USD0.75%$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI1247.37万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM905.85万0.01%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF458.61万0.00%954億 USD0.05%$235+0.80%
JPMorgan U.S. Tech Leaders ETFJTEK410.97万0.08%48.99億 USD0.65%$107.91+1.80%
ALPS Medical Breakthroughs ETFSBIO233.76万1.22%1.91億 USD0.50%$55.04+2.03%
iShares Russell 2000 Growth ETFIWO220万0.02%139.72億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO214.62万0.01%180億 USD0.06%$112.66+0.50%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFJPMorgan U.S. Tech Leaders ETFJTEKALPS Medical Breakthroughs ETFSBIOiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
